More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$11.32B
EPS
-1.06
P/E ratio
--
Price to sales
--
Dividend yield
--
Beta
-1.498678
Previous close
$15.08
Today's open
$15.20
Day's range
$14.06 - $15.20
52 week range
$12.07 - $29.23
show more
CEO
Robert W. Duggan
Employees
265
Headquarters
Miami, FL
Exchange
NASDAQ Global Market
Shares outstanding
799763918
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
The FDA declined to approve one of biotech's most closely watched cancer drugs
The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.
Market Watch • 15 hours ago

Summit Therapeutics Faces FDA Hurdle For Lead Lung Cancer Drug, Stock Tumbles
Summit Therapeutics Inc. (NASDAQ:SMMT) is trading at a 52-week low on Monday after the FDA rejected the company's lead cancer drug application.
Benzinga • 16 hours ago

Summit Stock Falls on FDA Rejection for Lung Cancer Drug
SMMT's shares plunge 20% as the FDA issues a CRL for ivonescimab, citing insufficient overall survival evidence despite positive progression-free survival results.
Zacks Investment Research • 10 hours ago

2 Cancer-Drug Developers Seeing Unusual Options Volume
Two cancer drug developers are seeing unusual options activity today, with Summit Therapeutics Inc (NASDAQ:SMMT) and CG Oncology Inc (NASDAQ:CGON) moving in opposite directions following major clinical and regulatory developments.
Schaeffers Research • 10 hours ago

Summit's FDA Setback Is a Reality Check for Next-Gen Cancer Drugs
Summit Therapeutics stock sinks as regulators decline to approve ivonescimab, a next-generation cancer therapy backed by AstraZeneca.
Barrons • 15 hours ago

FDA Doesn't Approve Summit's China-Developed Lung Cancer Drug
The FDA said Summit Therapeutics' lung cancer drug ivonescimab, developed in China, failed to show a statistically significant survival benefit.
Investors Business Daily • Nov 15, 2026

Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for ivonescimab in combination with platinum-containing chemotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), who have received prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy.
Business Wire • Nov 15, 2026

Wall Street Analysts See a 62.33% Upside in Summit Therapeutics (SMMT): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 62.3% in Summit Therapeutics (SMMT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks Investment Research • Nov 10, 2026

SMMT's Q3 Earnings Beat Estimates, Ivonescimab Development in Focus
Summit reports Q3 loss narrower than expected and posts nil sales. Ivonescimab advances through late-stage studies and new oncology collaborations.
Zacks Investment Research • Nov 5, 2026

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today reported its financial results for the third quarter and nine months ended September 30, 2026, and provided an update on clinical and operational progress. “This quarter marked a period of meaningful momentum for Summit, highlighted by AstraZeneca's $2 billion strategic equity investment and the expansion of our network of clinical collaborations with AstraZeneca, Daiichi Sankyo, and several others,” said Robert W. Duggan, Ch.
Business Wire • Nov 4, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Summit Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.